• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型隐球菌荚膜启动替代补体途径激活的早期事件。

Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

作者信息

Kozel T R, Wilson M A, Murphy J W

机构信息

Department of Microbiology, University of Nevada, Reno 89557.

出版信息

Infect Immun. 1991 Sep;59(9):3101-10. doi: 10.1128/iai.59.9.3101-3110.1991.

DOI:10.1128/iai.59.9.3101-3110.1991
PMID:1831795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC258140/
Abstract

The capsule of Cryptococcus neoformans is a powerful activator of the alternative complement pathway. This study examined the manner in which the cryptococcal capsule influences initiation of and early events in complement activation by C. neoformans. These studies examined the effects of the classical and alternative pathways on the kinetics and early sites for deposition of C3 fragments on encapsulated cryptococci, nonencapsulated cryptococci, and zymosan. The results showed that nonencapsulated cryptococci and zymosan are qualitatively and quantitatively similar in the manner in which they initiate complement activation. Both utilize the classical and alternative pathways. Initiation via the classical pathway occurs suddenly and simultaneously at sites distributed over the entire cell surface. Initiation of the alternative pathway by zymosan and nonencapsulated cryptococci is characterized by a lag of 6 to 8 min before appreciable amounts of C3 accumulate on the cells. Alternative pathway initiation by zymosan and nonencapsulated cryptococci occurs at a limited number of focal initiation sites that expand with alternative pathway amplification to cover the cell surface. Presence of the cryptococcal capsule blocks classical pathway initiation, which would normally occur at the cryptococcal cell wall, and produces an initiation that is dependent solely on the alternative pathway. Initiation of the alternative pathway by the cryptococcal capsule is characterized by a lag in C3 accumulation and the appearance of a limited number of focal initiation sites which resemble those observed when the alternative pathway is activated by zymosan and nonencapsulated cryptococci.

摘要

新型隐球菌的荚膜是替代补体途径的强力激活剂。本研究探讨了隐球菌荚膜影响新型隐球菌补体激活起始及早期事件的方式。这些研究考察了经典途径和替代途径对C3片段在被包囊的隐球菌、无荚膜隐球菌和酵母聚糖上沉积的动力学及早期位点的影响。结果显示,无荚膜隐球菌和酵母聚糖在启动补体激活的方式上在定性和定量方面相似。二者均利用经典途径和替代途径。通过经典途径启动补体激活在整个细胞表面分布的位点突然且同时发生。酵母聚糖和无荚膜隐球菌通过替代途径启动补体激活的特征是,在相当数量的C3在细胞上积累之前有6至8分钟的延迟。酵母聚糖和无荚膜隐球菌通过替代途径启动补体激活发生在有限数量的局灶性起始位点,这些位点随着替代途径的放大而扩展以覆盖细胞表面。隐球菌荚膜的存在会阻断通常在隐球菌细胞壁发生的经典途径启动,并产生仅依赖替代途径的启动。隐球菌荚膜通过替代途径启动补体激活的特征是C3积累有延迟以及出现有限数量的局灶性起始位点,这些位点类似于酵母聚糖和无荚膜隐球菌激活替代途径时所观察到的位点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/94b628bedb04/iai00045-0263-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/035e216c1993/iai00045-0260-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/a11754fa84c3/iai00045-0261-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/f050f49e8f80/iai00045-0262-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/94b628bedb04/iai00045-0263-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/035e216c1993/iai00045-0260-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/a11754fa84c3/iai00045-0261-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/f050f49e8f80/iai00045-0262-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e956/258140/94b628bedb04/iai00045-0263-a.jpg

相似文献

1
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.新型隐球菌荚膜启动替代补体途径激活的早期事件。
Infect Immun. 1991 Sep;59(9):3101-10. doi: 10.1128/iai.59.9.3101-3110.1991.
2
Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.正常人血清中的抗体对C3早期沉积于荚膜型和非荚膜型新生隐球菌的作用。
Infect Immun. 1992 Mar;60(3):754-61. doi: 10.1128/iai.60.3.754-761.1992.
3
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.通过使用由六种分离蛋白重构的替代补体途径,C3调理素片段在荚膜新生隐球菌上的激活与结合。
Infect Immun. 1989 Jul;57(7):1922-7. doi: 10.1128/iai.57.7.1922-1927.1989.
4
Activation of the complement system by the capsule of Cryptococcus neoformans.新型隐球菌荚膜激活补体系统。
Curr Top Med Mycol. 1993;5:1-26.
5
Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.C3与荚膜型和非荚膜型新生隐球菌结合及激活过程中扩增阶段的动力学分析
Infect Immun. 1992 Aug;60(8):3122-7. doi: 10.1128/iai.60.8.3122-3127.1992.
6
Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.白色念珠菌启动经典和替代补体途径的独特特征。
Infect Immun. 1996 Aug;64(8):3360-8. doi: 10.1128/iai.64.8.3360-3368.1996.
7
Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.当C3b与新型隐球菌荚膜结合时,C3b加速降解为iC3b。
Infect Immun. 1993 Oct;61(10):4360-6. doi: 10.1128/iai.61.10.4360-4366.1993.
8
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.菌株变异、血清型及结构修饰对C3激活及与新型隐球菌结合动力学的影响。
Infect Immun. 1993 Jul;61(7):2966-72. doi: 10.1128/iai.61.7.2966-2972.1993.
9
Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.不依赖Fc的人抗甘露聚糖抗体介导的C3沉积至白色念珠菌的替代途径激活的特征。
Mol Immunol. 2009 Jan;46(3):473-80. doi: 10.1016/j.molimm.2008.10.008. Epub 2008 Nov 26.
10
Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.被包囊和未被包囊的新型隐球菌的趋化性发生及替代补体途径的激活
Infect Immun. 1979 Nov;26(2):435-40. doi: 10.1128/iai.26.2.435-440.1979.

引用本文的文献

1
Cryptococcosis in Pediatric Renal Transplant Recipients: Comparative Insights from Adult Cases.儿童肾移植受者的隐球菌病:来自成人病例的比较见解。
Medicina (Kaunas). 2025 Jun 18;61(6):1108. doi: 10.3390/medicina61061108.
2
Proteasome inhibition as a therapeutic target for the fungal pathogen .蛋白酶体抑制作为真菌病原体的治疗靶点。
Microbiol Spectr. 2023 Sep 26;11(5):e0190423. doi: 10.1128/spectrum.01904-23.
3
Mechanisms of fungal dissemination.真菌传播的机制。

本文引用的文献

1
Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.新型隐球菌非包被变异株 I. 毒力研究及可溶性多糖的特性。
Infect Immun. 1971 Feb;3(2):287-94. doi: 10.1128/iai.3.2.287-294.1971.
2
The use of lead citrate at high pH as an electron-opaque stain in electron microscopy.在电子显微镜检查中,将高pH值的柠檬酸铅用作电子不透明染色剂。
J Cell Biol. 1963 Apr;17(1):208-12. doi: 10.1083/jcb.17.1.208.
3
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Cell Mol Life Sci. 2021 Apr;78(7):3219-3238. doi: 10.1007/s00018-020-03736-z. Epub 2021 Jan 15.
4
Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis.隐球菌病期间对新型隐球菌和格特隐球菌的免疫
Fungal Genet Biol. 2015 May;78:76-86. doi: 10.1016/j.fgb.2014.11.006. Epub 2014 Dec 12.
5
A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule.LHC1在新型隐球菌荚膜的高阶结构和补体结合中的作用。
PLoS Pathog. 2014 May 1;10(5):e1004037. doi: 10.1371/journal.ppat.1004037. eCollection 2014 May.
6
Lymphocyte transformation assay for C neoformans antigen is not reliable for detecting cellular impairment in patients with neurocryptococcosis.新型隐球菌抗原淋巴细胞转化试验不可靠,不能用于检测神经隐球菌病患者的细胞损伤。
BMC Infect Dis. 2012 Oct 30;12:278. doi: 10.1186/1471-2334-12-278.
7
Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody.细菌体积越小,越能逃避补体作用,而抗体的凝集作用则能克服这一点。
Cell Host Microbe. 2011 Nov 17;10(5):486-96. doi: 10.1016/j.chom.2011.09.009.
8
A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infection.一种用于评估新型隐球菌感染中宿主-病原体相互作用的敏感高通量检测方法。
PLoS One. 2011;6(7):e22773. doi: 10.1371/journal.pone.0022773. Epub 2011 Jul 28.
9
In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.在体外,C3 在隐球菌荚膜上的沉积是通过多种补体激活途径发生的。
Mol Immunol. 2011 Sep;48(15-16):2009-18. doi: 10.1016/j.molimm.2011.06.215. Epub 2011 Jul 1.
10
Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.脑膜炎奈瑟菌 W-135 群和 Y 荚膜多糖出人意料地增强补体替代途径的激活。
J Biol Chem. 2011 Mar 11;286(10):8297-8307. doi: 10.1074/jbc.M110.184838. Epub 2011 Jan 18.
替代补体途径初始C3转化酶的形成。通过天然C3中假定硫酯的自发水解获得C3b样活性。
J Exp Med. 1981 Sep 1;154(3):856-67. doi: 10.1084/jem.154.3.856.
4
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.新型隐球菌A血清型荚膜多糖的结构与抗原活性
Mol Immunol. 1980 Aug;17(8):1025-32. doi: 10.1016/0161-5890(80)90096-6.
5
Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans.新型隐球菌半乳甘露聚糖的分级分离与特性分析
Carbohydr Res. 1984 Feb 15;125(2):343-9. doi: 10.1016/0008-6215(84)85172-1.
6
Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils.血清成分对巨噬细胞和中性粒细胞吞噬新生隐球菌的调理作用的定位。
Infect Immun. 1984 Feb;43(2):574-9. doi: 10.1128/iai.43.2.574-579.1984.
7
The alternative pathway of complement.补体替代途径
Springer Semin Immunopathol. 1984;7(2-3):163-92. doi: 10.1007/BF01893019.
8
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.替代补体途径激活过程中的C3b沉积及其在激活表面的沉积效应。
J Immunol. 1983 Oct;131(4):1930-5.
9
Purification and structural studies on the complement-system control protein beta 1H (Factor H).补体系统调控蛋白β1H(H因子)的纯化及结构研究
Biochem J. 1982 Aug 1;205(2):285-93. doi: 10.1042/bj2050285.
10
Capsular polysaccharides of Cryptococcus neoformans.新型隐球菌的荚膜多糖
Rev Infect Dis. 1984 Sep-Oct;6(5):619-24. doi: 10.1093/clinids/6.5.619.